Abstract
Keywords
Introduction
Bacterial keratitis is a vision threating ocular infection. A large number of bacteria are present in the eye which includes Staphylococcus sp, Corynebacterium sp, and Streptococcussp (1). However, many other outside bacteria such as Pseudomonas aeruginosa can make tragic diseases and unfavorable results (2). Pseudomonasaeruginosa is a Gram-negative and ubiquitous bacteria that causes severe infections especially opportunistic infection in patients with immune deficiency (3). Recently, eye infections caused by Pseudomonasaeruginosa especially in hospitalized people with systemic diseases have been impressive (4). Pseudomonas keratitis occurs often followed by severe corneal ulceration or perforation (5). This infection can progress rapidly and lead to vision loss or complete blindness (6). Third and fourth generation of Fluoroquinolones such as Ciprofloxacin and Ofloxacin are used as choice drugs for the treatment of bacterial keratitis, especially Pseudomonas keratitis (7). Pseudomonasaeruginosa can acquire antibiotics resistance in several ways (3). So, the emergence of Pseudomonas resistant strains to antibiotics isn’t unexpected particularly using just one type of antibiotic (8). According to the increasing antibiotic resistant infections in hospitals, the development and application of the alternatives to antibiotic are necessary (9). From centuries metals such as silver, copper, gold, and aluminum have been used for treating wound infections (10, 11). More than 2000 years ago, the therapeutic properties of Silver have been known (12). Ag-NPs are toxic to bacteria at low concentrations. Also, these particles have anti-viral, anti-fungal, and anti-inflammatory effects (13). Several in-vitro studies have been done on the combination of antibiotics and metal nanoparticles against Gram-positive and Gram-negative bacteria. The results showed that they have synergistic effect on bacteria but Gram-negative bacteria were more susceptible than Gram-positive (14). This biological feature can be useful in the rapid treatment of bacterial infections such as Pseudomonas keratitis. In the present study, we compared the effects of eight different treatment combinations in the treatment process of Pseudomonas keratitis.
Experimental
Animals
Sixty eight New Zealand male rabbits with weighting 1.5-3 kg were obtained from Razi institute, Tehran, Iran. The animals were fed with water and alfalfa hay. All animals were examined in terms of eye infection before starting the study. The infected animals were treated according to the guidelines of the association for research in vision and ophthalmology.
Silver nanoparticles, Ciprofloxacin and Betamethasone preparation
Solution of Ag-NPs with 40-50 nm size and 4000 mg l-1 concentration was prepared (Malvern, USA). Also, Ciprofloxacin 3%, and Betamethasone 1% in the form of eye drops were purchased from drugstore (Sina Daru, Iran). Serial dilutions of Silver nanoparticles, Ciprofloxacin, and their combination were done by Muller Hinton broth (Merck, Germany) with the same mixture in the ratio 1:1 to determine the MIC and MBC. Then, 0.2 mL of bacterial suspension (105 CFU mL-1) was inoculated into the tubes containing different concentration of them (15).
MIC and MBC of Ciprofloxacin (µg mL-1) Ag-NPs (mg L-1) and their combination
| Group | MIC | MBC |
|---|---|---|
| Ciprofloxacin | 5.85 | 11.71 |
| Silver nanoparticles | 15.62 | 31.25 |
| Ciprofloxacin + Silver nanoparticles | 0.73 | 1.46 |
| 0.97 | 1.95 |
The details of Kruskal-Wallis test of corneal opacity scores (Mean rank) among all treatment groups
| 108 h | 204 h | |
|---|---|---|
| Chi-Square | 25.422 | 26.647 |
| df | 7 | 7 |
| Asymp. Sig.* | 0.001 | 0.000 |
Comparison of corneal opacity scores (Mean rank) between two groups
| Group | 108 h | 204 h |
|---|---|---|
| CO + | 28.00c | 28.00b |
| N | 26.00c | 26.00b |
| N+B | 22.00c | 24.00b |
| C+N+B | 10.50b | 7.50c |
| C+B | 13.38bc | 13.63c |
| C | 16.25bc | 15.75c |
| C+N | 13.38bc | 13.63c |
| CO − | 2.50a | 3.50a |
The details of ANOVA test of number of days of blepharospasm and ocular discharge (Mean ± SD) among all treatment groups
| Variable Time | Blepharospasm 108 h | Ocular discharge 108 h | Blepharospasm 204 h | Ocular discharge 204 h |
|---|---|---|---|---|
| Sum of Squares | 54.969 | 54.875 | 191.5000 | 168.000 |
| df | 7 | 7 | 7 | 7 |
| F | 251.286 | 188.43 | 82.071 | 57.600 |
| Sig.* | 0.000 | 0.000 | 0.000 | 0.000 |
Comparison of number of days of blepharospasm and ocular discharge (Mean ± SD) between two groups
| Group | Blepharospasm 108 h | Ocular discharge 108 h | Blepharospasm 204 h | Ocular discharge 204 h |
|---|---|---|---|---|
| CO + | 4.00 ± 0.00c | 4.00 ± 0.00c | 8.00 ± 0.00f | 8.00 ± 0.00e |
| N | 4.00 ± 0.00c | 4.00 ± 0.00c | 7.25 ± 0.50ef | 7.25 ± 0.50de |
| N+B | 4.00 ± 0.00c | 4.00 ± 0.00c | 7.00 ± 0.00def | 7.00 ± 0.00cde |
| C+N+B | 3.25 ± 0.50b | 3.50 ± 0.57b | 3.25 ± 0.50b | 4.00 ± 0.81b |
| C+B | 4.00 ± 0.00c | 4.00 ± 0.00c | 5.75 ± 1.25cd | 5.50 ± 1.29bcd |
| C | 4.00 ± 0.00c | 4.00 ± 0.00c | 6.50 ± 0.57cde | 6.25 ± 0.50cd |
| C+N | 4.00 ± 0.00c | 4.00 ± 0.00c | 5.25 ± 0.50c | 5.75 ± 0.50cd |
| CO − | 0.00 ± 0.00a | 0.00 ± 0.00a | 0.00 ± 0.00a | 0.25 ± 0.50a |
The details of ANOVA test of bacterial counts (log CFU mL-1) (Mean ± SD) among all treatment groups
| 108 h | 204 h | |
|---|---|---|
| Sum of Squares | 341.469 | 634.969 |
| df | 7 | 7 |
| F | 67.870 | 129.972 |
| Sig.* | 0.000 | 0.000 |
Comparison of bacterial counts (log CFU mL-1).(Mean ± SD) between two groups
| Group | 108 h | 204 h |
|---|---|---|
| CO + | 11.25 ± 0.92d | 15.00 ± 0.81d |
| N | 6.50 ± 1.29c | 6.50 ± 1.29c |
| N+B | 7.50 ± 1.29c | 6.50 ± 1.29c |
| C+N+B | 2.50 ± 0.57ab | 1.50 ± 0.57ab |
| C+B | 3.50 ± 0.57b | 2.50 ± 0.57b |
| C | 3.50 ± 0.57b | 2.50 ± 0.57b |
| C+N | 2.75 ± 0.50b | 1.75 ± 0.50ab |
| CO − | 0.75 ± 0.50a | 0.50 ± 0.57a |
Induction of experimental keratitis
Pseudomonasaeruginosa PAO1 was obtained from McMaster University, Canada by Dr. Nima Hoseini Jazani, School of Medicine, Urmia University.
The Muller Hinton agar (Merck, Germany) medium was used for bacterial growth. Pseudomonas keratitis was created by Suspension 0.5 McFarland of bacteria. After standardization, the concentration of bacterial suspension changed to 105 CFU mL-1 (5). For experimental induction keratitis the rabbit’s immune system was weakened by Azathioprine (Ramopharmin, Iran). It was administrated orally three consecutive days with 5 mg kg-1 dose and until inoculation bacteria 1 mg kg-1 dose (a maintenance dose) to rabbits. Given that any manipulation of the cornea is painful, in order to comply with ethical principles and rules of animal rights as well as to prevent animal heave during the process of creating keratitis, anesthesia induction was performed with Ketamine hydrochloride (35 mg kg-1 dose, Worden, Holland) and Xylazine hydrochloride (3.5 mg kg-1 dose, Worden, Holland). Also, one drop Lidocaine (Aburaihan, Iran) was prescribed in each eye in order to numb the cornea. Using an insulin syringe with a needle size 30, ten microliters of bacterial suspension (105 CFU/mL) were inoculated into each cornea. The needle was placed horizontally and tangent in the corneal surface and injected about 0.2 mm into the corneal stroma. Fifteen to 20 minutes late rabbits regained consciousness.
Treatment groups
The rabbits were randomly divided into eight equal groups. The medication in each group was as follows:
CO −: Negative control group, rabbits without bacterial inoculation; CO +: Positive control group, treated using with saline; C: treated using with Ciprofloxacin; N: treated using with Ag-NPs; C+B: treated using with Ciprofloxacin and Betamethasone; N+B: treated using with Ag-NPs and Betamethasone; C+N: treated using with Ciprofloxacin and Ag-NPs; C+N+B: treated using with Ciprofloxacin, Ag-NPs and Betamethasone.Twelve hours after bacterial inoculation four times daily treatment of groups were done (according to the institutional ethical committee guidelines). In fact, the duration of treatment was 108 post infection for four rabbits in each group and 204h for the rest of the rabbits.
Clinical evaluation of experimental Pseudomonas keratitis
Twelve h after bacterial inoculation, daily eye exams and evaluating clinical symptoms were done. Three clinical factors were considered in this study: the number of days of ocular discharge, and blepharospasm, and also corneal opacity. Corneal opacity was scored based on 0-3 with a decreasing trend at 12, 108, and 204 h after bacterial inoculation. The rating system used to grade corneal opacity was in this way: grade 0, Lack of corneal opacity; grade 1, faint opacity; grade 2, Iris fade; grade 3, and Lack of pupil (16).
Bacterial count
Four rabbits of each group were euthanized using CO2 at108 and 204h after inoculation following general anesthesia with Xylazine and Ketamine. The eyes were bugged out with a gap in the middle of the eye by scissors under sterile conditions. Then the corneas were dissected from the eyes with a sterile scalpel blade and homogenized in one mL of 1% protease peptone. After vortexing to determine the number of bacteria (CFU) per milliliter, 10 µL of the each homogenized cornea were diluted 1:10000 in sterile saline. Then, 100 µL of each diluted sample was plated in triplicate on Mueller Hinton agar medium and incubated for 24 h at 37 °C (6). The plates that had 30 to 300 bacterial colonies were counted and the average results of each cornea were reported as log10 CFU mL-1.
Data statistical analysis
Data analyzing was done by SPSS statistical software, version 18. Scoring corneal opacity results of the groups were analyzed statistically by Kruskal-Wallis test. Also, Mann-Whitney U-test was used to compare differences between two groups. One-way analysis of variance (ANOVA) was performed on the number of days of blepharospasm, ocular discharge, and bacterial counts. Tukey’s test was used to find out the difference between the different groups in the event the (ANOVA) was significant. Also, P value less than 0.05 was significant.
Results
MIC and MBC determination
The results showed that the MIC and MBC of Ag-NPs in combination with Ciprofloxacin were less than each of them alone (Table 1).
Clinical evaluation of experimental Pseudomonas keratitis
Twelve h post inoculation, all eyes were infected. The mean rank of opacity scores of all infected rabbits weren’t significantly different between any of the groups at this time (Kruskal-Wallis, P > 0.05) (Figure 1). Also, the differences between the means ± standard deviation of the number of days of blepharospasm and ocular discharge of all treatment groups except CO − weren’t significant in the first 48 h (ANOVA, P > 0.05) (Figure 2).
At the end of 108 and 204 h, corneal opacity in the C+N+B group was better than others that it was significantly less than that observed in groups CO +, CO −, N and N+B (Mann-Whitney U-test, P < 0.05) (Table 2 and Table 3, Figure 2).
Also, the means number of days of blepharospasm and ocular discharge in C+N+B group were significantly less than other groups at the end of treatment period. Of course, at 204 h post infection it wasn’t significant between groups C+N+B and C+B for ocular discharge (Table 4 and Table 5).
Bacterial count
ANOVA showed significant difference among the eight groups at 108 and 204 h (P < 0.0005) (Table 6). The mean bacterial count (log CFU mL-1) in C+N+B group was less than others except CO −. According to post-hoc test it was significantly different with CO +, N and N+B groups at 108 and 204 h. Also, there were no significant difference between CO − and C+N+B at 108 h and CO − with C+N+B and C+N at 204 h post infection (Table 7).
Discussion
Pseudomonas aeruginosa is an opportunistic pathogen which can cause severe corneal infections (17). It can quickly produce progressive necrosis of the corneal stroma (18). Unlike other mucosal surfaces, healthy cornea has no blood and lymph vessels and immune system (19). Any injury to the corneal epithelium makes it susceptible to acute infections (20). Hosting features, such as the immune system status as well as microbial virulence factors are important in the incidence of corneal infections. Fluoroquinolones have excellent in-vitro activity against a wide range of Gram-negative and Gram-positive organisms (21). Due to the consequences of long-term antibiotic use, it is a critical need to identify new antibacterial compounds and new method to prevent and treat bacterial infections. Onlen et al. used Propolis in the treatment of experimental Pseudomonas keratitis in rabbit. They said: “Our results revealed that Propolis has a very limited effect when used alone on both bacterial count and corneal opacity compared with any of drug combinations involving Ciprofloxacin on experimental rabbit model of P. aeruginosa keratitis” (6). In our results it was also observed that Ag-NPs cannot be a replacement for antibiotic, although combination of them had a positive strong influence on variables assessed especially in the presence of Betamethasone. In-vitro antibacterial effects of Ag-NPs against Pseudomonas aeruginosa were confirmed by various studies (22-26). Similar to other studies (27-29) the MIC and MBC results of Ag-NPs in combination with Ciprofloxacin in this study were less than using each of them alone. In some studies, Ag-NPs were combined with other materials in order to enhance their antibacterial activity. For example, combination of Ag-NPs and Chitosan acetate were evaluated against Pseudomonas aeruginosa in burn patients. This product showed significant inhibitory effects in preventing infections caused by Pseudomonas aeruginosa (30). Also, Mirzaei et al. reported that Allicin with Ag-NPs had synergistic effect against skin infection caused by Pseudomonas aeruginosa (31). The acquisition of antibiotics resistance by Pseudomonas aeruginosa is a concern of exclusive antibiotic treatment. Using Ag-NPs in combination with an antibiotic can be a good idea to prevent bacterial resistance. A large number of studies’ results demonstrated synergistic effect of Ag-NPs in combination with antibiotics against bacteria especially Pseudomonas aeruginosa (28, 32, 33). In our results at the end of treatment period bacterial counts (log CFU mL-1) in C+N+B and C+N groups were less than others except CO – and also these groups did not have any significant differences with CO – group. It can confirm synergistic effect of combination Ag-NPs and Ciprofloxacin against Pseudomonas aeruginosa PAO1 in in-vivo condition. Using of Ag-NPs to treat eye infections less has been done in the past. One reason may be obscurity about the toxic effects of Ag-NPs on mammalian eye. Santoro et al. emphasized that it depends on Ag-NPs diameter size. So that Ag-NPs with a large size (40 nm and larger) did not have significant toxicity on the eye cells and other mammalian cell lines (34).
Conclusion
The results of the present study do not allow any final conclusions. To this aim, more studies of Ag-NPs ocular side effects as an adjutant in keratitis treatment must be done. However, our results confirmed that the combination of Ag-NPs with a specific antibiotic such as Ciprofloxacin have a positive synergistic influence on Pseudomonas keratitis treatment. According to corneal opacity scores, the number of days of blepharospasm, and ocular discharge, it seems that keratitis treatment process in C+N+B group was better than traditional treatment method with Ciprofloxacin and Betamethasone. It seems that using combination of them against Pseudomonas aeruginosa has the following advantages: 1. Enhancement of the their antibacterial effects and as a result decrease inthe therapeutic dose of each of them in compared to using either alone. 2. Decrease in the genetic mutations probability in bacteria against antibiotic in combination with Ag-NPs and thus decrease in the emergence of resistant Pseudomonas strains.
Acknowledgements
References
-
1.
Frizon L, Araújo MC, Andrade L, Zorat Yu MC, Wakamatsu TH, Lima ALH, Pereira Gomes JA. Evaluation of conjunctival bacterial flora in patients with Stevens-Johnson Syndrome. Clinics (Sao Paulo). 2014;69:168-72. [PubMed ID: 24626941].
-
2.
Aileen Sy, Srinivasan M, Mascarenhas J, Lalitha P, Rajaraman R, Ravindran M, Oldenburg CE, Ray KJ, Glidden D, Zegans ME, McLeod SD, Lietman TM, Acharya NR. Pseudomonas aeruginosa Keratitis: Outcomes and Response to Corticosteroid Treatment. Invest. Ophthalmol. Vis. Sci. 2012;53:267-72. [PubMed ID: 22159005].
-
3.
Denayer S, Matthijs S, Cornelis P. Pyocin S2 (Sa) kills Pseudomonas aeruginosa strains via the FpvA type I ferripyoverdine receptor. J. Bacteriol. 2007;189:7663-8. [PubMed ID: 17720787].
-
4.
Singh K, Panghal M, Kadyan S, Chaudhary U, Yadav JP. Green Silver nanoparticles of Phyllanthus amarus: as an antibacterial agent against multi drug resistant clinical isolates of Pseudomonas aeruginosa. J. Nanobiotechnol. 2014;12:40.
-
5.
Nejabat M, Masoumpour M, Eghtedari M, Azarpira N, Ashraf M, Astane A. Amniotic membrane transplantation for the treatment of Pseudomonas keratitis in experimental rabbits. Iran. Red. Crescent. Med. J. 2009;11:149-54.
-
6.
Onlen Y, Tamer C, Oksuz H, Duran N, Altug ME, Yakan S. Comparative trial of different anti-bacterial combinations with propolis and ciprofloxacin on Pseudomonas keratitis in rabbits. Microbiol. Res. 2007;162:62-8. [PubMed ID: 16904302].
-
7.
Parmar P, Salman A, Kalavathy CM, Kaliamurthy J, Prasanth DA, Thomas PA, Jesudasan CA. Comparison of topical gatifloxacin 03% and ciprofloxacin 03% for the treatment of bacterial keratitis. Am. J. Ophthalmol. 2006;141:282-6. [PubMed ID: 16458681].
-
8.
Palanisamy NK, Ferina N, Amirulhusni AN, Mohd-Zain Z, Hussaini J, Ping LJ, Durairaj R. Antibiofilm properties of chemically synthesized Silver nanoparticles found against Pseudomonas aeruginosa. J. Nanobiotechnol. 2014;12:2.
-
9.
Goli HR, Nahaei MR, Ahangarzadeh Rezaee M, Hasani A, Samadi Kafil H, Aghazadeh M. Emergence of colistin resistant Pseudomonas aeruginosa at Tabriz hospitals, Iran. Iran. J. Microbiol. 2016;8:62-9. [PubMed ID: 27092226].
-
10.
Deng Y, Li J, Yu J, Zhao J, Tang J. Silver nanoparticles well-dispersed in amine-functionalized, one-pot made vesicles as an effective antibacterial agent. Mater. Sci. Eng. C. Mater. Biol. Appl. 2016;60:92-9. [PubMed ID: 26706511].
-
11.
Kujda M, Oćwieja M, Adamczyk Z, Bocheńska O, Braś G, Kozik A, Bielańska E, Barbasz J. Charge stabilized Silver nanoparticles applied as antibacterial agents. J. Nanosci. Nanotechnol. 2015;15:3574-83. [PubMed ID: 26504979].
-
12.
Prabhu S, Poulose E. Silver nanoparticles: mechanism of antimicrobial action, synthesis, medical applications, and toxicity effects. Int. Nano. Lett. 2012;2:32.
-
13.
Chen M, Yang Z, Wu H, Pan X, Xie X, Wu C. Antimicrobial activity and the mechanism of silver nanoparticle thermosensitive gel. Int. J. Nanomed. 2011;6:2873-7.
-
14.
Birla SS, Tiwari VV, Gade AK, Ingle AP, Yadav AP, Rai MK. Fabrication of Silver nanoparticles by Phoma glomerata and its combined effect against Escherichia coli, Pseudomonas aeruginosa and Staphylococcus aureus. Lett. Appl. Microbiol. 2009;48:173-9. [PubMed ID: 19141039].
-
15.
Goda H, Ramakrishna Y, Autar KM. Evaluation of minimum inhibitory and minimum bactericidal concentration of nano-silver base inorganic anti-microbial agent (Novaron®) against Streptococcus mutans. Contemp. Clin. Dent. 2012;3:288-93. [PubMed ID: 23293483].
-
16.
Wei C, Zhu M, Petroll WM, Robertson DM. Pseudomonas aeruginosa Infectious Keratitis in a High Oxygen Transmissible Rigid Contact Lens Rabbit Model. Invest. Ophthalmol. Vis. Sci. 2015;55:5890-9.
-
17.
Gellatly SL, Hancock REW. Pseudomonas aeruginosa: new insights into pathogenesis and host defenses. Pathog Dis. 2013;67:159-73. [PubMed ID: 23620179].
-
18.
Al-Mujaini A, Al-Kharusi N, Thakral A, Wali UK. Bacterial Keratitis: Perspective on Epidemiology, Clinico-Pathogenesis, Diagnosis and Treatment. Sultan. Qaboos. Univ. Med. J. 2009;9:184-95. [PubMed ID: 21509299].
-
19.
Niederkorn JY, Larkin DFP. Immune Privilege of Corneal Allografts. Ocul. Immunol. Inflamm. 2010;18:162-71. [PubMed ID: 20482389].
-
20.
Gonzalez L, Loza RJ, Han KY, Sunoqrot S, Cunningham C, Purta P, Drake J, Jain S, Hong S, Chang JH. Nanotechnology in Corneal Neovascularization Therapy-A Review. J. Ocul. Pharmacol. Ther. 2013;29:124-34. [PubMed ID: 23425431].
-
21.
Hayashi K, Takahata M, Kawamura Y, Todo Y. Synthesis, antibacterial activity, and toxicity of 7-(isoindolin-5-yl)-4-oxoquinoline-3-carboxylic acids Discovery of the novel des-F(6)-quinolone antibacterial agent garenoxacin (T-3811 or BMS-284756). Arzneimittelforschung. 2002;52:903-13. [PubMed ID: 12572531].
-
22.
Mapara N, Sharma M, Shriram V, Bharadwaj R, Mohite KC, Kumar V. Antimicrobial potentials of Helicteres isora Silver nanoparticles against extensively drug-resistant (XDR) clinical isolates of Pseudomonas aeruginosa. Appl. Microbiol. Biotechnol. 2015;99:10655-67. [PubMed ID: 26362684].
-
23.
Ramalingam B, Parandhaman T, Das SK. Antibacterial effects of biosynthesized Silver nanoparticles on surface ultrastructure and nanomechanical properties of gram-negative bacteria viz Escherichia coli and Pseudomonas aeruginosa. ACS. Appl. Mater. Interfaces. 2016;8:4963-76. [PubMed ID: 26829373].
-
24.
Arokiyaraj S, Vincent S, Saravanan M, Lee Y, Oh YK, Kim KH. Green synthesis of Silver nanoparticles using Rheum palmatum root extract and their antibacterial activity against Staphylococcus aureus and Pseudomonas aeruginosa. Artif. Cells. Nanomed. Biotechnol. 2016;45:372-9. [PubMed ID: 27023851].
-
25.
Silva Santos K, Barbosa AM, Pereira da Costa L, Pinheiro MS, Oliveira MB, Ferreira Padilha F. Silver Nanocomposite Biosynthesis: Antibacterial Activity against Multidrug-Resistant Strains of Pseudomonas aeruginosa and Acinetobacter baumannii. Molecules. 2016;21:1255-61.
-
26.
Jadhav K, Dhamecha D, Bhattacharya D, Patil M. Green and ecofriendly synthesis of silver nanoparticles: Characterization, biocompatibility studies and gel formulation for treatment of infections in burns. J. Photochem. Photobiol. B. 2016;155:109-15. [PubMed ID: 26774382].
-
27.
Nasiri A, Afsar Gharebagh R, Nojoumi SA, Akbarizadeh MR, Harirchi S, Arefnezhad M, Sahraei S, Hesaraki M, Afshari M, Javadian F, Sheykhzade Asadi M, Shahi Z, Sargazi A. Evaluation of the Antimicrobial Activity of Silver nanoparticles on Antibiotic-Resistant Pseudomonas aeruginosa. Int. J. Basic Sci. Med. 2016;1:25-8.
-
28.
Panáček A, Smékalová M, Kilianová M, Prucek R, Bogdanová K, Večeřová R. Strong and Nonspecific Synergistic Antibacterial Efficiency of Antibiotics Combined with Silver nanoparticles at Very Low Concentrations Showing No Cytotoxic Effect. Molecules. 2015;21:E26. [PubMed ID: 26729075].
-
29.
Habasha MB, Parkb AJ, Visb EC, Harrisc RJ, Khursigarab C. Synergy of Silver nanoparticles and Aztreonam against Pseudomonas aeruginosa PAO1 Biofilms. Antimicrob. Agents Chemother. 2014;58:5818-30. [PubMed ID: 25049240].
-
30.
Huang L, Dai T, Xuan Y, Tegos GP, Hamblin MR. Synergistic combination of chitosan acetate with nanoparticle silver as a topical antimicrobial: efficacy against bacterial burn infections. Antimicrob. Agents Chemother. 2011;55:3432-8. [PubMed ID: 21502618].
-
31.
Mirzaei F, Salouti M, Shapouri R, Alizadeh H. Antibacterial effect of allicin, silver nanoparticles, and their combination against skin infection due to Pseudomonas aeruginosa in Animal model. J. Fasa Uni. Med. Sci. 2014;4:311-7.
-
32.
Prema P, Thangapandiyan S, Immanuel G. CMC stabilized Silver nanoparticles synthesis, characterization and its antibacterial and synergistic effect with broad spectrum antibiotics. Carbohydr. Polym. 2017;158:141-8. [PubMed ID: 28024537].
-
33.
Rahim KAAA, Mohamed AMA. Bactericidal and Antibiotic Synergistic Effect of Silver nanoparticles against Methicillin-Resistant Staphylococcus aureus. Jundishapur J. Microbiol. 2015;8:e25867. [PubMed ID: 26862383].
-
34.
Santoro CM, Duchsherer NL, Grainger DW. Antimicrobial efficacy and ocular cell toxicity from silver nanoparticles. Nanobiotechnology. 2007;3:55-6. [PubMed ID: 19865601].